期刊文献+

阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的疗效观察 被引量:6

下载PDF
导出
摘要 目的:研究骨质疏松症患者使用阿仑膦酸钠联合注射用骨肽治疗的临床效果及影响。方法:选取我院2010年9月~2013年9月期间收治的120例骨质疏松症患者,所有患者按随机数字表法被分为两组,每组60例,其中对照组60例患者使用阿仑膦酸钠联合钙尔奇进行治疗,观察组60例患者使用阿仑膦酸钠联合注射用骨肽进行治疗。结果:两组患者治疗后对比发现,观察组总有效率高达93.33%,远高于对照组的80%,P〈0.05;对比骨密度发现,观察组患者升高程度比对照组患者更为明显,P〈0.05;观察组不良反应发生率仅为5%,远小于对照组的13.33%,P〈0.05。结论:骨质疏松症患者使用阿仑膦酸钠联合注射用骨肽进行治疗效果显著,不良反应少,值得临床推广应用。
作者 赵爱玲
出处 《北方药学》 2015年第1期78-79,共2页 Journal of North Pharmacy
  • 相关文献

参考文献6

二级参考文献31

  • 1刘忠厚,潘子昂,王石麟.原发性骨质疏松症诊断标准的探讨[J].中国骨质疏松杂志,1997,3(1):1-15. 被引量:139
  • 2李景田,邹锦慧,张慧明,李伯灵,何文英,周小璜,李沐吉.序贯应用甲状旁腺素和二膦酸盐预防激素性骨质疏松的实验研究[J].广东医学,2006,27(4):473-475. 被引量:5
  • 3张秀珍,宋利格,李红,韩峻峰,钱国峰,贺铭,李颖,谷磊.阿伦膦酸钠对绝经后骨质疏松症患者骨密度、细胞因子及骨代谢指标的影响[J].中华内科杂志,2006,45(7):565-568. 被引量:17
  • 4Delmas PD. The use of bisphosphonates in the treatment of osteoporo- sis. Current Opinion in Rheumatology,2005,17 (4) :462 - 466.
  • 5Brown JP, Prince RL, Deal C,et al. Comparison of the Effect of De- nosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass:A Randomized, Blinded, Phase 3 Trial. J Bone Miner Res, 2009, 14:1-34.
  • 6Lems WF, Lodder MC, Lips P,et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low - dose prednisone : a randomized, double - blind, placebo - controlled trial. Osteoporos Int ,2006,17 (5) :716 - 723.
  • 7Iwamoto J, Sato Y, Takeda T, et al. Hip fracture protection by alendr- onate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging,2008,3 (3) :483 - 489.
  • 8Rhee Y, Kang M, Min Y,et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean post- menopausal women:a multicenter, double - blind, randomized, pla- cebo - controlled study. Osteoporos Int,2006,17 (12) : 1801 - 1807.
  • 9Trabulus S, Ahiparmak MR, Apaydin S, et al. Treatment of renal transplant recipients with low bone mineral density:a randomized pro- spective trial of alendronate, alfacaleidol, and alendronate combined with alfacalcidol. Transplant Proc,2008,40( 1 ) :160 -- 166.
  • 10Bergmann P, Body JJ, Boonen S,et al. Evidence - based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consen- sus document of the Belgian Bone Club. lnt J Clin Pract,2009,63 (1) :19 -26.

共引文献69

同被引文献40

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部